Takeda’s Andy Plump Tells The Japanese Pharma’s New Story
R&D President Discusses ‘Wave 1’ Drugs, Deal-Making Priorities
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?
